Dr. Lindsay A. Rosenwald operates as a founder and chairman of the group of companies known as Paramount Capital group. These companies specialize in investment banking, venture capital, asset management, and direct investing within the biotechnology and life-sciences industry.
As a Wall Street biotechnology entrepreneur, Dr. Rosenwald is also a member of the Orion Biomedical Fund, LP and Orion Biomedical Offshore Fund, LP. These investment companies both participate in financing start-up pharmaceutical research labs. Dr. Lindsay Rosenwald and his team seek out cutting edge bio-pharma companies and provide the needed capital for their research to move forward and he is responsible for the founding and re-capitalization of dozens of public and private companies.
Dr. Lindsay Rosenwald and the Paramount Capital portfolio of companies have found success with three new chemical entities recently approved by the Food and Drug Administration (FDA). They currently have dozens of other compounds in the clinical trial stage. One of the portfolio companies, PolaRx BioPharmaceuticals, Inc., has recently received final marketing approval for its leukemia drug called arsenic trioxide. The approval came quickly, only 30 months after the initial patient was treated in a corporate clinical trial.
One of his more successful acquisitions, Cougar Biotechnology, developed an exciting drug for late stage prostate cancer called abiraterone acetate. Dr. Lindsay Rosenwald has financed or founded a long list of other cutting edge companies such as Genta, Inc, Repligen Corporation, Cypress Bioscience, Inc., Discovery Laboratories, Inc., and Avigen, Inc.
Dr. Rosenwald graduated from Pennsylvania State University majoring in Finance and Economy graduating Beta Gamma Sigma in 1977. From 1977 to 1979, Dr. Rosenwald worked as an independent management consultant for several health care businesses. Later, he entered Temple University School of Medicine and graduated in 1983. Next Dr. Rosenwald took an internship at Abington Medical Hospital, working in a private medical practice until 1986. At this time, he took a position on Wall Street serving as a financial analyst specializing in medical research investment opportunities.
Today, Dr. Lindsay Rosenwald is well known in both the world of investing and the medical research field. He is a visionary with an eye toward innovation in drug research and development. He has over 20 years of experience in these areas and focuses on creating and promoting pioneering medical technologies that will enhance and transform the horizons of today’s life sciences and biotechnology companies.
Related posts:
Leave a comment